Document is current

Article History

Accepted: 23 April 2025

First Online: 22 May 2025

Declarations

:

: Association Vaincre la Mucoviscidose, Filière Maladies Rares MUCO-CFTR, Société Française de la Mucoviscidose.

: The authors report no conflict of interest directly relating to this manuscript. PRB has received personal fees for lectures/advisory boards from Astra Zeneca, Chiesi, Insmed, Pfizer, Sanofi, MSD, Viatris, Vertex and support for travelling to meetings by Astra-Zeneca and Chiesi. CM has received personal fees for lectures/advisory boards from Astra Zeneca, GSK, Vertex and Zambon. NC has received personal fee for an advisory board from MSD France. All other authors have no conflict of interest.

: The study was not registered as it is not mandatory in France for real-word studies. It was approved by the Institutional Review Board of the French Society for Respiratory Medicine (Société de Pneumologie de Langue Française) (#2020-003).

: The study was approved by the Institutional Review Board of the French Society for Respiratory Medicine (Société de Pneumologie de Langue Française) (#2020-003). In accordance with French laws, written consent was not required, as the study did not require any intervention outside usual care. The observational nature of the study was confirmed by the Agence Nationale de Sécurité du Médicament et des Produits de Santé. Patients received written information on the study’s goals and design and on the use of their medical data before inclusion. Vertex Pharmaceuticals played no role in the acquisition or analysis of data, in the writing of the manuscript, or in the decision to submit this manuscript.

: Not applicable.

: The data that support the findings of this study are not publicly available but are available from the corresponding author upon reasonable request.

: The code used for data processing and analysis is provided in the Supplementary Information.

: Concept and design: PRB, SB, JMT. Acquisition of data: LFB, GL, NC, JDS, JF, RK, IH, CM, PRB, SB. Analysis and interpretation of data: PM, PRB, SB. Drafting of the manuscript: PM, NB, FF, SB, PRB. Critical revision of the manuscript for important intellectual content: All authors.